Research programme: microbial therapeutics - Vedanta Biosciences

Drug Profile

Research programme: microbial therapeutics - Vedanta Biosciences

Alternative Names: Microbiome-based therapeutics - Vedanta; VE 303

Latest Information Update: 22 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vedanta Biosciences
  • Developer NYU Langone Medical Center; Vedanta Biosciences
  • Class Anti-infectives; Anti-inflammatories; Antineoplastics; Immunotherapies
  • Mechanism of Action Helper-inducer T-lymphocyte stimulants; Immunomodulators; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Clostridium infections
  • Research Autoimmune disorders

Most Recent Events

  • 21 Jul 2017 Preclinical trials in Clostridium infections in USA (unspecified route) (Vedanta Biosciences pipeline, July 2017)
  • 30 May 2017 Vedanta Biosciences has patent protection for microbial therapeutics in USA
  • 16 May 2017 Vedanta Biosciences has patent protection for microbial therapeutics in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top